GlassScriptPhysician profile
Michael Guccione
NPI 1902893340
$802.67
in general payments reported to CMS, 2019-2025
11 companies · $21.43 in 2025
The $21.43 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.70 · 2020: $40.07 · 2021: $28.25 · 2022: $32.15 · 2023: $407 · 2024: $212 · 2025: $21.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $640.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $382.92 | 2019-2024 | Tavneos, Parsabiv, Krystexxa |
| Horizon Therapeutics Plc | $107.40 | 2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $72.12 | 2024 | Velphoro |
| Travere Therapeutics, INC. | $51.79 | 2023 | |
| Glaxosmithkline, LLC. | $43.08 | 2024 | Jesduvroq, Benlysta |
| Vifor Pharma, INC. | $34.51 | 2023 | Veltassa |
| Ardelyx, INC. | $25.73 | 2024 | Ibsrela |
| Boston Scientific Corporation | $23.40 | 2023 | Watchman Flx |
| Calliditas Therapeutics US INC. | $21.96 | 2024 | |
| Akebia Therapeutics INC | $21.43 | 2025 | Vafseo |
| Mallinckrodt Enterprises LLC | $18.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Guccione listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.